91 related articles for article (PubMed ID: 27308523)
1. Taspase 1: A protease with many biological surprises.
Niizuma H; Cheng EH; Hsieh JJ
Mol Cell Oncol; 2015; 2(4):e999513. PubMed ID: 27308523
[TBL] [Abstract][Full Text] [Related]
2. Uncleaved TFIIA is a substrate for taspase 1 and active in transcription.
Zhou H; Spicuglia S; Hsieh JJ; Mitsiou DJ; Høiby T; Veenstra GJ; Korsmeyer SJ; Stunnenberg HG
Mol Cell Biol; 2006 Apr; 26(7):2728-35. PubMed ID: 16537915
[TBL] [Abstract][Full Text] [Related]
3. Species selectivity of mixed-lineage leukemia/trithorax and HCF proteolytic maturation pathways.
Capotosti F; Hsieh JJ; Herr W
Mol Cell Biol; 2007 Oct; 27(20):7063-72. PubMed ID: 17698583
[TBL] [Abstract][Full Text] [Related]
4. TASP1 is deleted in an infant with developmental delay, microcephaly, distinctive facial features, and multiple congenital anomalies.
Suleiman J; Mundt M; Sampath S; El-Hattab AW
Clin Genet; 2018 Jul; 94(1):170-173. PubMed ID: 29633245
[TBL] [Abstract][Full Text] [Related]
5. Taspase1-dependent TFIIA cleavage coordinates head morphogenesis by limiting Cdkn2a locus transcription.
Takeda S; Sasagawa S; Oyama T; Searleman AC; Westergard TD; Cheng EH; Hsieh JJ
J Clin Invest; 2015 Mar; 125(3):1203-14. PubMed ID: 25664857
[TBL] [Abstract][Full Text] [Related]
6. TFIIA transcriptional activity is controlled by a 'cleave-and-run' Exportin-1/Taspase 1-switch.
Schrenk C; Fetz V; Vallet C; Heiselmayer C; Schröder E; Hensel A; Hahlbrock A; Wünsch D; Goesswein D; Bier C; Habtemichael N; Schneider G; Stauber RH; Knauer SK
J Mol Cell Biol; 2018 Feb; 10(1):33-47. PubMed ID: 28992066
[TBL] [Abstract][Full Text] [Related]
7. Peptidyl succinimidyl peptides as taspase 1 inhibitors.
van den Boom J; Mamić M; Baccelliere D; Zweerink S; Kaschani F; Knauer S; Bayer P; Kaiser M
Chembiochem; 2014 Oct; 15(15):2233-7. PubMed ID: 25146997
[TBL] [Abstract][Full Text] [Related]
8. A facelift for the general transcription factor TFIIA.
Høiby T; Zhou H; Mitsiou DJ; Stunnenberg HG
Biochim Biophys Acta; 2007; 1769(7-8):429-36. PubMed ID: 17560669
[TBL] [Abstract][Full Text] [Related]
9. Regulation of MLL/COMPASS stability through its proteolytic cleavage by taspase1 as a possible approach for clinical therapy of leukemia.
Zhao Z; Wang L; Volk AG; Birch NW; Stoltz KL; Bartom ET; Marshall SA; Rendleman EJ; Nestler CM; Shilati J; Schiltz GE; Crispino JD; Shilatifard A
Genes Dev; 2019 Jan; 33(1-2):61-74. PubMed ID: 30573454
[TBL] [Abstract][Full Text] [Related]
10. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
11. The Taspase1/Myosin1f-axis regulates filopodia dynamics.
Hensel A; Stahl P; Moews L; König L; Patwardhan R; Höing A; Schulze N; Nalbant P; Stauber RH; Knauer SK
iScience; 2022 Jun; 25(6):104355. PubMed ID: 35601920
[TBL] [Abstract][Full Text] [Related]
12. Unraveling the Activation Mechanism of Taspase1 which Controls the Oncogenic AF4-MLL Fusion Protein.
Sabiani S; Geppert T; Engelbrecht C; Kowarz E; Schneider G; Marschalek R
EBioMedicine; 2015 May; 2(5):386-95. PubMed ID: 26137584
[TBL] [Abstract][Full Text] [Related]
13. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
14. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia.
Liang K; Volk AG; Haug JS; Marshall SA; Woodfin AR; Bartom ET; Gilmore JM; Florens L; Washburn MP; Sullivan KD; Espinosa JM; Cannova J; Zhang J; Smith ER; Crispino JD; Shilatifard A
Cell; 2017 Jan; 168(1-2):59-72.e13. PubMed ID: 28065413
[TBL] [Abstract][Full Text] [Related]
16. Evolutionary divergence of Threonine Aspartase1 leads to species-specific substrate recognition.
Wünsch D; Hahlbrock A; Heiselmayer C; Bäcker S; Schrenk C; Benne F; Schilling O; Knauer SK
Biol Chem; 2015 Apr; 396(4):367-76. PubMed ID: 25720119
[TBL] [Abstract][Full Text] [Related]
17. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
[TBL] [Abstract][Full Text] [Related]
18. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
19. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
20. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
